济南泌尿系感染什么引起(济南早泄应该如何自治) (今日更新中)

BEIJING, Sept. 18 (Xinhua) -- No newly-formed oil belt was detected in the past two days in north China's Bohai Bay from ConocoPhillips' platforms in the Penglai 19-3 oilfield, the State Oceanic Administration (SOA) said.However, new spots of visible oil spills could still be found around platform C, the SOA said in a statement on Sunday.It is estimated that about 4.51 liters of oil leaked into the sea on Saturday, a slight drop from 6.56 liters from Thursday.No oil clean-up work was done on Friday and Saturday due to the strong winds and rough conditions at sea, the statement said.ConocoPhillips China, a subsidiary of U.S. energy giant ConocoPhillips, first reported spills to authorities in June. The oil spills have polluted more than 5,500 square km of sea water in the Bohai Bay since June.The oil spills have spread to beaches in Hebei and Liaoning provinces. The spills have been blamed for losses in the provinces' tourism and aquatic farming industries.The company on Aug. 31 submitted a report to the SOA claiming that it had screened out all potential sources for oil spills and blocked all oil leaks.After days of evaluation, however, the SOA said on Sept. 2 that ConocoPhillips had failed to complete the clean-up.

GENEVA, Aug. 12 (Xinhua) -- 18 people seeking treatment at hospitals in Somalia had been confirmed cholera positive through laboratory tests, the Geneva based World Health Organization (WHO) said on Friday.The 18 positive cases were detected out of 30 stool samples collected from patients seeking treatment at hospitals for acute watery diarrhea, a symptom that could result from cholera, WHO spokesperson Tarek Jasarevic told reporters.All confirmed cases, including residents of Mogadishu district and those among internally displaced persons (IDPs), were said to be tested positive for the Vibrio cholera serotype "inaba", which had been the predominant serotype in Somalia for the past three years."These results are an alarming reminder of the critical situation in Mogadishu and other parts of Southern, Central Somalia, (which are) still experiencing drought, population displacement and conflict," Jasarevic said.WHO has reported a dramatic increase of acute watery diarrhea cases in Somalia.In June and July alone, 1,633 acute watery diarrhea cases had been registered in Banadir Hospital, Mogadishu, representing 38 percent of all reported cases in 2011, and a sharp rise comparing with the same period last year.The United Nations public health arm said the situation was related to poor sanitation and limited access to safe water in numerous informal IDP settlements and a limited capacity of existing health partners to access those settlements and provide essential health services.In addition, the high number of malnourished children due to the ongoing famine increased the susceptibility to waterborne diseases.

HOUSTON, July 25 (Xinhua) -- A shelter-in-place was ordered after a battery caught fire during a testing at NASA's Johnson Space Center Monday morning.A battery was being tested inside a containment system when it got overheated and caught fire at about 9 a.m. local time, ABC quoted the Houston Fire Department (HFD) sources as reporting.A shelter-in-place was issued for a few buildings because it's believed that one of the bi-products of the combustion could be dangerous, HFD said.The fire was put out before 11:30 a.m.A firefighter was injured when a hydrant cap blew off and struck him, according to ABC.

HELSINKI, July 4 (Xinhua) -- A new Finnish research shows that sleeplessness may be hereditary, and insomniacs are more likely to die earlier than people with healthy sleep patterns.The research is the first to link insomnia with mortality risk, Finnish media reported on Monday.The research is conducted by the Institute of Occupational Health in collaboration with the University of Helsinki and the Finnish National Institute for Health and WelfareIn a large-scale twin study, the Finnish researchers followed the health status of 12,500 adult twin pairs during the years from 1990 to 2009. Twenty percent of the participants were suffering from sleeplessness symptoms, including difficulty in initiating sleep, nocturnal awakening and non-restorative sleep.The study found out that compared with unidentical twins, identical twins were more likely to suffer from similar insomnia symptoms. This finding indicates that genetic factors play a role in the formation of insomnia.Moreover, the participants were divided into three groups, according to their sleep qualities. Out of the participants, 48 percent were good sleepers, 40 percent average sleepers and 12 percent poor sleepers. The search result shows that insomnia-related symptoms may increase mortality risk.In addition, compared with good sleepers, 7 percent of the women and 22 percent of the men who were average sleepers were more likely to die earlier; and poor sleepers were 1.5 times more likely to die earlier.According to the researchers, sleeplessness is a common health problem among working-age cohort. Chronic sleeplessness raises the risk of many illnesses and accidents, and thus weakens people's quality of life and ability to operate properly.The experts suggest that insomniacs should seek medical treatment in time, and chronic insomnia patients should be better treated with non-drug therapy.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

来源：资阳报